Neurocrine Biosciences (NBIX) Highlighted As Today's Perilous Reversal Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Neurocrine Biosciences ( NBIX) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Neurocrine Biosciences as such a stock due to the following factors:

  • NBIX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $48.7 million.
  • NBIX has traded 51,780 shares today.
  • NBIX is down 3.5% today.
  • NBIX was up 5.7% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NBIX with the Ticky from Trade-Ideas. See the FREE profile for NBIX NOW at Trade-Ideas

More details on NBIX:

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently there are 8 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Neurocrine Biosciences has been 1.1 million shares per day over the past 30 days. Neurocrine has a market cap of $3.4 billion and is part of the health care sector and drugs industry. The stock has a beta of -0.91 and a short float of 9.4% with 4.83 days to cover. Shares are up 79.2% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Inovio, Neurocrine, Alnylam

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Wall Street Closes Lower Amid Continued Global Worries